Press "Enter" to skip to content

AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure

  • AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain management.
  • The study will evaluate the efficacy and safety of Dsuvia for perioperative management of surgical pain in patients on buprenorphine treatment.
  • Endpoints include overall perioperative opioid use, length of post-anesthesia care unit recovery time, outpatient prescription opioid use over the first 24 hours after discharge home, and adverse events.
  • Data will be compared to the historical matched control patients on buprenorphine treated with standard IV opioids in the perioperative setting.
  • Dsuvia, known as Dzuveo in Europe, is indicated for use in adults to manage acute pain severe enough to require an opioid analgesic for which alternative treatments are inadequate.
  • Price Action: ACRX shares are up 0.25% at $1.51 on the last check Thursday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *